ABSI vs. OABI, ORIC, MXCT, INNV, IGMS, ABUS, ALT, AVTE, IRMD, and YMAB
Should you be buying Absci stock or one of its competitors? The main competitors of Absci include OmniAb (OABI), ORIC Pharmaceuticals (ORIC), MaxCyte (MXCT), InnovAge (INNV), IGM Biosciences (IGMS), Arbutus Biopharma (ABUS), Altimmune (ALT), Aerovate Therapeutics (AVTE), Iradimed (IRMD), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "medical" sector.
OmniAb (NASDAQ:OABI) and Absci (NASDAQ:ABSI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations.
OmniAb has higher revenue and earnings than Absci. OmniAb is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.
OmniAb has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Comparatively, Absci has a beta of 2.39, indicating that its stock price is 139% more volatile than the S&P 500.
In the previous week, Absci had 10 more articles in the media than OmniAb. MarketBeat recorded 19 mentions for Absci and 9 mentions for OmniAb. Absci's average media sentiment score of 0.74 beat OmniAb's score of -0.03 indicating that OmniAb is being referred to more favorably in the media.
72.1% of OmniAb shares are owned by institutional investors. Comparatively, 52.1% of Absci shares are owned by institutional investors. 7.0% of OmniAb shares are owned by insiders. Comparatively, 9.8% of Absci shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
OmniAb presently has a consensus target price of $9.00, indicating a potential upside of 102.25%. Absci has a consensus target price of $9.25, indicating a potential upside of 100.43%. Given Absci's higher probable upside, equities research analysts plainly believe OmniAb is more favorable than Absci.
OmniAb has a net margin of -301.62% compared to OmniAb's net margin of -2,042.01%. Absci's return on equity of -19.93% beat OmniAb's return on equity.
Absci received 4 more outperform votes than OmniAb when rated by MarketBeat users. However, 100.00% of users gave OmniAb an outperform vote while only 53.66% of users gave Absci an outperform vote.
Summary
OmniAb beats Absci on 10 of the 16 factors compared between the two stocks.
Get Absci News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
